No COVID Vaccine Approval Yet, Drug Regulator Analysing SII and Bharat Biotech Data

Vaccine makers Serum Institue of India (SII) and Bharat Biotech, who are expecting a nod for approval of emergency use, the Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee on Wednesday stated that it was still doing the analyses of the additional data and information submitted by SII and Bharat Biotech. The next meeting of the drug regulator will take place on January 1.//

The Subject Expert Committee met on Wednesday to consider the Emergency Use Authorisation (EUA) request of Pfizer, SII, and Bharat Biotech Private Ltd.

Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.

‘Analysis of the additional data and information submitted by the Serum Institute of India and Bharat Biotech is still being conducted by the regulator Central Drug Standard Control Organisation's Subject Expert Committee. ’

Tweet it Now

Further time was requested on behalf of Pfizer, while the additional data and information presented by the SII and Bharat Biotech were perused and analyzed by the SEC.

"The analysis of the additional data and information is going on. SEC will convene again on 1st January 2021 (Friday)," the Centre said in a statement.

America's Pfizer was the first one to apply for the accelerated approval on December 4, followed by the SII and Bharat Biotech, who applied on December 6 and 7, respectively.

COVID-19: Diet Plan and Lifestyle Modifications for the Unlock Phase
Healthy eating habits and adherence to physical activity are required during COVID-19 lockdown. WHO has prepared a set of general tips that you could follow during the lockdown to stay fit and healthy.

On December 9, the Subject Expert Committee had asked the SII and Bharat Biotech to submit more data and information to get approval.

The expert panel had then recommended the SII to submit the outcome of the assessment of the UK regulator for grant of emergency use approval, the updated safety data of the Phase 2/3 clinical trial, and immunogenicity data from the clinical trials in the UK and India.

Indian Namaste the Preferred Greeting over Conventional Handshake
COVID-19 pandemic is causing changes in how we greet each other. The traditional Indian way of greeting with folded hands (Namaste) is now being preferred over handshake. Namaste has more to it than just being a greetings, read to find out

Bharat Biotech was recommended to present the safety and efficacy data from the ongoing Phase 3 clinical trial in the country for further consideration.

Their applications were reviewed again earlier on Wednesday, hours after the UK accepted the recommendation of the Medicines and Healthcare Regulatory Agency (MHRA) to authorize Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use.

Current Vaccines Will Protect Against New Coronavirus Strains: Govt
COVID-19 vaccines will work against novel variants of the virus, and there is no data that current vaccines will fail to protect against the SARS-CoV-2 mutants found in South Africa or UK.

The authorization was significant for India as the Pune-based SII had tied up with the company to conduct clinical trials and manufacture the vaccine. Besides, Bharat Biotech is developing the country's indigenous coronavirus vaccine - Covaxin - in collaboration with the Indian Council of Medical Research.

The Central government plans to vaccinate nearly 30 crore people in the first phase of the drive. It will be offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crores elderly, mostly above the age of 50 years with co-morbidities.

Covishield uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

After vaccination, the surface spike protein is produced, priming the immune system to attack the coronavirus if it later infects the body.

The vaccine can be stored, transported, and handled at normal refrigerated conditions at two to eight degrees Celsius for at least six months and administered within existing healthcare settings.

Its interim analysis for efficacy showed that the vaccine was 70.4 percent effective at preventing symptomatic COVID-19 occurring more than 14 days after receiving two doses of the vaccine.

The SII has already made 40 to 50 million doses of the shot. "We have 40-50 million doses of Covishield stockpiled. We will be producing around 300 million doses by July 2021," its CEO Adar Poonawalla had recently said.

Besides this, Bharat Biotech's Covaxin is India's indigenous vaccine and is being developed in collaboration with the ICMR's National Institute of Virology.

The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.

Source-IANS